Growth Factors & Signaling

Sermorelin (GHRH 1–29 Amide)

For Research Use Only. Not for Human or Veterinary Use.

Overview

Sermorelin is the 29-amino-acid N-terminal fragment of growth-hormone-releasing hormone (GHRH 1–29) — the shortest fragment that keeps full GHRH activity. It is a full GHRH-receptor agonist and was historically used as a diagnostic agent for growth-hormone deficiency. In research it is used to probe the somatotropic axis and pituitary GH dynamics. It is a research compound.

Chemical Profile

PropertyValue
CAS number86168-78-7
ClassGHRH(1–29) fragment, C-terminal amide
Amino-acid sequenceTyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂
One-letter codeYADAIFTNSYRKVLGQLSARKLLQDIMSR-NH₂ (29 aa)
Molecular formulaC₁₄₉H₂₄₆N₄₄O₄₂S
Molecular weight≈ 3357.9 g/mol
Purity (HPLC)≥ 98%
Sermorelin at a glance
Class
GHRH(1–29) amide fragment
Research status
GH research; formerly a diagnostic agent
Study routes
Subcutaneous, intravenous
Half-life
≈ 12 min
Key feature
Shortest fully active GHRH fragment

Mechanism of Action

Sermorelin reproduces the action of natural GHRH: it binds the GHRH receptor on pituitary somatotrophs and, through Gαs and cAMP, stimulates the synthesis and pulsatile release of growth hormone. Because it works upstream on the pituitary, GH output stays subject to the body’s normal feedback, and it has a very short half-life — the opposite end of the spectrum from CJC-1295.

ComponentDetail
Primary targetGHRH receptor (GHRH-R)
G-protein couplingGαs → adenylyl cyclase → cAMP → PKA
GH releaseStimulates natural pulsatile GH secretion
FeedbackGH output remains under normal somatostatin feedback
DurationShort-acting (minutes)

Pharmacology

ParameterValue
Half-life (t½)≈ 12 min
Bioavailability (SC)≈ 60–70%
Time to peak (Tmax)≈ 15–30 min
MetabolismProteolytic degradation
Route of administrationSubcutaneous, intravenous
EliminationRenal (peptide fragments)

Research Evidence

Representative studies and their focus are named below; specific numerical outcomes are not restated here as claims.

Study typeResearch focusReference
GH-stimulation testingGHRH-receptor agonism / GH-deficiency diagnosticsGHRH / sermorelin clinical literature
Somatotropic-axis researchPituitary GH dynamics and pulsatilityGHRH literature
Aging GH-axis researchGH/IGF-1 responses to GHRHGHRH literature

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
Reliable GH release; used in GH-deficiency testingGH-stimulation testingGHRH literature
Physiological, short-acting GHRH-receptor probesomatotropic-axis researchGHRH literature

For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.

Dosing & Reconstitution Reference

Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.

ParameterReference value
Research dose range (literature)≈ 200–500 µg per injection, in study protocols
Reconstitution solventBacteriostatic water (0.9% benzyl alcohol)
Storage (lyophilized)−20°C, protected from light
Storage (reconstituted)2–8°C, up to ~2–3 weeks
Do not useIf the solution is cloudy or contains particulates

Safety Profile

Published research observations, provided for reference only. This material is not for human or veterinary use.

CategoryPublished observations
Local tolerabilityMild injection-site reactions
HormonalNo significant prolactin or cortisol elevation (GHRH mechanism)
GeneralWell tolerated in reported GH-testing use
StatusFor research use only; not for human or veterinary application

Physicochemical Properties

PropertyValue
Physical stateWhite to off-white lyophilized powder
Solubility (water)Soluble
logP≈ −2.5 (hydrophilic)
pH (reconstituted)5.0–7.0
Stability (lyophilized)≥ 24 months at −20°C

Synthesis & Manufacturing

Sermorelin is a 29-residue C-terminally amidated peptide made by Fmoc solid-phase synthesis. Its length and the single oxidation-sensitive methionine make coupling efficiency and cleavage the steps that need the most care.

StepDetail
StrategyFmoc solid-phase peptide synthesis
ResinRink amide resin (C-terminal amide)
Sensitive residueMet protected against oxidation; scavengers at cleavage
CouplingHBTU / HOBt with DIPEA
CleavageTFA / TIPS / H₂O with thiol scavengers
PurificationPreparative RP-HPLC (C18, TFA/ACN gradient)
  • Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
  • Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
  • Critical quality attributes: correct molecular weight and low deletion-peptide content. A single methionine is oxidation-sensitive; use scavengers at cleavage and protect solutions.

Analytical Methods

MethodParameterTypical result
RP-HPLC (C18, UV 214 nm)Purity≥ 98%
HPLC retentionC18, reversed-phase TFA/ACN gradientSingle main peak
ESI-MS (positive mode)Identity / mass[M+H]⁺ ≈ 3358 Da
MALDI-TOFMass confirmation[M+H]⁺ ≈ 3358 Da
Amino-acid analysisCompositionConsistent with the stated sequence
LC-MS (extracted ion)Deletion-peptide impuritiesWithin specification
Karl FischerWater content< 6%
LAL assayEndotoxinWithin specification
Ion chromatographyResidual TFA< 500 ppm

Representative RP-HPLC purity method:

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
  • Gradient: reversed-phase TFA/ACN gradient · Flow rate: 1.0 mL/min · Detection: UV 214 nm
  • Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 3358 Da). A single methionine is oxidation-sensitive; use scavengers at cleavage and protect solutions.

Stability Data

Representative stability behaviour under common storage, handling and formulation conditions.

ConditionDurationResult
Lyophilized, −20°C, dark≥ 24 monthsNo significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark≥ 12 monthsMinimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)3 months< 5% degradation
Reconstituted, 2–8°C, dark7–14 daysMinor degradation
Reconstituted, 25°C24–48 hUse promptly
Light exposure (ICH Q1B)1.2 M lux·hGenerally light-stable
Freeze–thaw (−20°C ⇄ 25°C)3 cyclesAcceptable — aliquot to avoid repeats
  • Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
  • Minimise freeze-thaw cycles; aliquot material used across many sessions.
  • Key factor: A single methionine is oxidation-sensitive; use scavengers at cleavage and protect solutions.

Selected References

  • GHRH(1–29) / sermorelin pharmacology and GH-stimulation-test literature.
  • Reviews of GHRH analogues and the somatotropic axis.

Quality & Supply

  • HPLC ≥ 98% purity with a Certificate of Analysis per batch
  • Identity confirmed by LC-MS
  • Research samples through to bulk, with worldwide delivery
  • Custom quantities and packaging on request

Need Sermorelin — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote